Unicycive Therapeutics Inc Stock

$0.63

18.38% yesterday

Nasdaq, Jun 11, 10:19 pm CET

ISIN

US90466Y1038

Symbol

UNCY

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Services

Industry

Various services

Overview Dividends Analysts Charts News Strategies

Unicycive Therapeutics Inc Stock price

$0.63

-5.22 89.23% 5Y

Nasdaq, Closing price Wed, Jun 11 2025

+0.10 18.38%

ISIN

US90466Y1038

Symbol

UNCY

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Services

Industry

Various services

Key metrics

Market capitalization	$75.98m
Enterprise Value	$56.21m
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	6.69
Free Cash Flow (TTM) Free Cash Flow	$-31.10m
Cash position	$19.77m
P/E forward	negative
P/S forward	5.15
EV/Sales forward	3.81
Short interest	0.31%

As a Free StocksGuide user, you can view scores for all 6,842 stocks worldwide.

Get Started for Free Today

Unicycive Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

8 Analysts have issued a Unicycive Therapeutics Inc forecast:

8x Buy

100%

More details on Analyst Estimates Including Price Targets

8 Analysts have issued a Unicycive Therapeutics Inc forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Unicycive Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	12 12	41% 41% -
- Research and Development Expense	20 20	55% 55% -
EBITDA	-32 -32	55% 55% -
- Depreciation and Amortization	0.02 0.02	100% 100% -
EBIT (Operating Income) EBIT	-32 -32	55% 55% -
Net Profit	-38 -38	20% 20% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Unicycive Therapeutics Inc Stock News

Neutral

GlobeNewsWire

●

2 days ago

Unicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

- The U.S. Food and Drug Administration (FDA) identified deficiencies at a third-party manufacturing vendor - FDA to provide final decision by PDUFA action date of June 28, 2025 LOS ALTOS, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY or the “Company”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today anno...

Neutral

GlobeNewsWire

●

21 days ago

Unicycive Therapeutics to Present at Upcoming Investor Conferences

LOS ALTOS, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer will present at two upcoming virtual investment conferences.

Neutral

GlobeNewsWire

●

22 days ago

Unicycive Therapeutics Announces Time Change for 2025 Annual Meeting of Stockholders

LOS ALTOS, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ: UNCY) (“Unicycive” or the “Company”), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced a change in the time of the 2025 Annual Meeting of Stockholders (the “Annual Meeting”). The previously announced date of the meeting (June 9, 2025) and locatio...

More Unicycive Therapeutics Inc News

Company Profile

Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. Its products include UNI-494, Renazorb, and UNI-220. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.

Head office	United States
CEO	Shalabh Gupta
Employees	14
Founded	2016
Website	unicycive.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now